Understanding and Preventing Hypoglycemia in Diabetes

IFEMA Convention Center - Feria de Madrid, Warsaw Hall, Avda. del Partenón, 5, 28042 Madrid, Spain

Madrid, Spain | Monday, September 9, 2024

Helmsley’s Type 1 Diabetes Program will host a one-day industry session on the occasion of the 60th Annual Meeting of the European Association for the Study of Diabetes.

Join us for this scientific meeting exploring the latest research in how alpha and delta cell dysfunction leads to hypoglycemia, and efforts to therapeutically restore the body’s ability to reverse it. Session themes will include:

Genetic and gene expression studies that aim to understand the cause of glucagon secretion defects in diabetes.
Understanding and restoring alpha cell function in type 1 diabetes and type 2 diabetes.
- Intrinsic, paracrine, and in vivo consequences in humans.
Clinical progress and regulatory perspectives regarding pharmacological strategies to prevent hypoglycemia.
Short talks and a poster session from submitted abstracts.

Note that this meeting is intended to focus on islet biology and the physiological response to hypoglycemia and not, for example, on automated insulin delivery, novel insulins, or beta cell replacement.

Speakers

Joan Camuñas-Soler, PhD, University of Gothenburg

Karen Hauda, JD, MS, Novo Nordisk

Richard Liggins, PhD, Zucara Therapeutics

Asger Lund, MD, PhD, Copenhagen University Hospital Gentofte

Marjana Marinac, PharmD, JDRF

Alvin C. Powers, MD, Vanderbilt University

Michael Rickels, MD, MS, University of Pennsylvania School of Medicine

Patrik Rorsman, PhD, Oxford University

Lori Sussel, PhD, University of Colorado Anschutz Medical Campus

Additional speakers to be announced

Scientific Organizing Committee

Marcela Brissova, PhD, Vanderbilt University Medical Center, United States

Shareen Forbes, MBChB, PhD, FRCP, University of Edinburgh, Scotland

Patrick Gilon, PhD, Université Catholique de Louvain, Belgium

Philippe Lysy, MD, PhD, Université Catholique de Louvain, Belgium

David Piston, PhD, Washington University in St. Louis, United States

Patrik Rorsman, PhD, Oxford University, England

Jason Winnick, PhD, University of Cincinnati, United States

Gina Yosten, PhD, St. Louis University School of Medicine, United States

Conchi Izquierdo, PhD, Helmsley Charitable Trust, United States

Benjamin Williams, PhD, Helmsley Charitable Trust, United States

Registration

Advance registration requested

We encourage those interested in attending to register in advance. Note that in-person admission will be on a first-come, first-served basis, and registration is required to attend the Helmsley session lunch. Virtual participation will be available for those unable to attend in-person.

Registration form

Note that separate registration for the EASD meeting is also required to attend. If you would like to register only for the one-day industry session, please email exh_reg_easd@interplan.de for more information.

Abstract Submission

Abstracts submissions are invited to be considered by the scientific committee for a poster session. Abstracts are no longer being accepted to be considered for short talks.

Submission guidelines are provided at the link below.

Agenda

9:00-9:10 AM

Welcome / Introduction
Alvin C. Powers, MD, Vanderbilt University

9:15-10:40 AM

Genetic and gene expression studies that aim to understand the cause of glucagon secretion defects in diabetes.
Session Chair: To be announced

9:15-9:45 AM Lori Sussel, PhD, University of Colorado Anschutz Medical Campus. Alphabet(a) soup: Unraveling cell fate decisions in the islet.
9:45-9:55 AM Q&A.
10:00-10:30 AM Joan Camuñas-Soler, PhD, University of Gothenburg. Cell Dysfunction in Diabetes: Insights from Single-Cell Studies.
10:30-10:40 AM Q&A.

10:45-11:00 AM

Break: Snacks and coffee

11:00 AM-12:00 PM

Short talks from on submitted abstracts
Session Chair: To be announced

11:00-11:15 AM Short talk 1
11:15-11:20 AM Q&A
11:20 -11:35 AM Short talk 2
11:35 -11:40 AM Q&A
11:40 -11:55 AM Short talk 3
11:55-12:00 PM Q&A

12:00-1:00 PM

Lunch

1:00-2:25 PM

Understanding and restoring alpha cell function in T1D and T2D: Intrinsic, paracrine, and in vivo consequences in humans.
Session Chair: To be announced

1:00-1:30 PM Patrik Rorsman, PhD, Oxford University
1:30-1:40 PM Q&A
1:45-2:15 PM Michael Rickels, MD, MS, University of Pennsylvania School of Medicine. Understanding and restoring alpha cell function in type 1 diabetes.
2:15-2:25 PM Q&A

2:30-2:45 PM

Break: Snacks and coffee

2:50-4:30 PM

Clinical progress and regulatory perspectives regarding pharmacological strategies to prevent hypoglycemia.
Session Chair: Marjana Marinac, PharmD, JDRF

2:50-3:00 PM Short talk 1 — Asger Lund, MD, PhD, Copenhagen University Hospital Gentofte
3:05-3:15 PM Short talk 2 — Richard Liggins, PhD, Zucara Therapeutics
3:20-3:30 PM Short talk 3 — Karen Hauda, JD, MS, Novo Nordisk
3:30-3:40 PM Short talk 4 — Marjana Marinac, PharmD, JDRF
3:40-4:30 PM Discussion Session
Karen Hauda, JD, MS, Novo Nordisk
Richard Liggins, PhD, Zucara Therapeutics
Asger Lund, MD, PhD, Copenhagen University Hospital Gentofte

4:30 PM

Closing Remarks

5:00-6:00 PM

Poster Session

Location

This session will be held at the IFEMA Convention Center – Feria de Madrid, Warsaw Hall, Avda. del Partenón, 5, 28042 Madrid, Spain.

The floorplan for the IFEMA Convention Center – Feria de Madrid can be found here under “Venue & Travel”.

Questions or concerns?

Please contact hypoglycemia@helmsleytrust.org.

More about Helmsley's Type 1 Diabetes Program

The Type 1 Diabetes (T1D) program is dedicated to helping the global T1D community live safer, better, and more fulfilling lives today while funding advancements in research and technology for a better tomorrow.